Sudeep Pharma Ltd IPO

The company generates a significant portion of its revenues from a limited number of customers and the loss of such customers or a decline in demand from such customers could adversely affect the company's business, results of operations, financial condition, and cash flows.

The company generated 66.43%, 65.84%, 67.64% and 77.01% of its revenue from operations from the company's pharmaceutical, food and nutrition segment, in the three months ended June 30, 2025 and Fiscals 2025, 2024 and 2023, respectively. Any adverse developments affecting this segment may adversely affect its business, results of operations, financial condition, and cash flows.

The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers and any manufacturing or quality control problems may subject us to regulatory action, damage its eputation and have an adverse effect on its business and results of operations.

Three of the company's four Manufacturing Facilities and one of its two R&D facilities are concentrated in a single region and any adverse developments affecting this region could have an adverse effect on the company's business, results of operations, financial condition and cash flows.

Any disruption, slowdown or shutdown in the company's manufacturing or R&D operations could adversely affect its business, results of operations, financial condition and cash flows.

The company generates a substantial portion of its revenue from operations from the company's export sales (58.68%, 59.27%, 64.43% and 68.45% of its revenue from operations for the three months ended June 30, 2025 and Fiscals 2025, 2024 and 2023, respectively) and any adverse developments in such regions, including the imposition of tariffs or other anti-sourcing legislation, could adversely affect the company's business, results of operations, financial condition and cash flows.

If the company is unable to introduce new products in a timely manner or if the products the company commercialize do not perform as expected, the company's business, results of operations, financial condition and cash flows may be adversely affected.

The company has recently undertaken the NSS Acquisition and may undertake similar acquisitions, investments, joint ventures or other strategic alliances in the future, which if unsuccessful, may adversely affect its business, results of operations and financial condition.

Any delay, interruption or reduction in the supply of raw materials and equipment to manufacture the company's products may adversely affect its business, results of operations, financial condition and cash flows.

The company's past performance may not be indicative of its future growth. The company may not be successful in implementing and managing its expansion and growth strategy effectively. Further, the company intend to diversify into different businesses beyond the pharmaceutical sphere, and failures to successfully implement such business ventures can negatively impact the company's results of operations and financial condition.